Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories
You may also be interested in...
Daiichi Sankyo and Biota Bring Next-gen Flu Drug To Japan; Continue Search For Western Partner
TOKYO - Daiichi Sankyo has received marketing and manufacturing approval in Japan for its second-generation long-acting neuraminidase inhibitor Inavir (laninamivir), bringing encouraging news to Daiichi Sankyo and Australian partner Biota, which have faced delays in snagging an ex-Japan partner for the drug
Daiichi Sankyo and Biota Bring Next-gen Flu Drug To Japan; Continue Search For Western Partner
TOKYO - Daiichi Sankyo has received marketing and manufacturing approval in Japan for its second-generation long-acting neuraminidase inhibitor Inavir (laninamivir), bringing encouraging news to Daiichi Sankyo and Australian partner Biota, which have faced delays in snagging an ex-Japan partner for the drug
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months